Model for Charcot-Marie Tooth Disease
This novel neutralising antibody-based approach offers an innovative and valuable therapeutic strategy for patients with neuropathic pain.
The present invention relates to a novel DNA delivery vector for targeted gene therapy, medical imaging and vaccination with increased efficacy over existing technologies. The platform comprises a phagemid hybrid with phage and recombinant adeno-associated virus (AAV) components.
Novel truncated fragments of von Willebrand factor (VWF) engineered by a team at Imperial College London.
Functionalised graphene for use as a nucleant
66aa, ~7kDa serine/threonine-rich protein (STp) derived from Lactobacillus plantarum, resistant to proteolysis and with an immunomodulatory effect representing a potential novel therapeutic for IBD.